Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
November 26, 2020
Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer
Kenneth Emancipator, Lingkang Huang, Deepti Aurora-Garg, et al.
JAMA Network Open
|
October 29, 2020
Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors
Changxia Shao, Gerald Li, Lingkang Huang, et al.
Molecular Diagnosis & Therapy
|
September 20, 2022
Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate
Ji Min Kim, Binnari Kim, Eunji Kim, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 13, 2020
Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer
Estrid Høgdall, Claus Høgdall, Thao Vo, et al.
Journal of Hepatology
|
December 15, 2010
Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma
Chun-Fang Xu, Brian H Reck, Vicki L Goodman, et al.
Breast Cancer Research : BCR
|
March 12, 2025
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study
Rebecca Dent, Javier Cortés, Yeon Hee Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Razvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, et al.
NPJ Breast Cancer
|
October 2, 2025
Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy
Javier Cortes, Oleg Lipatov, Seock-Ah Im, et al.
Journal for Immunotherapy of Cancer
|
February 26, 2022
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
Robert I Haddad, Tanguy Y Seiwert, Laura Q M Chow, et al.
The Journal of Pathology. Clinical Research
|
April 17, 2024
Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119
Javier Cortes, Eric P Winer, Oleg Lipatov, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
November 26, 2020
Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer
Kenneth Emancipator, Lingkang Huang, Deepti Aurora-Garg, et al.
JAMA Network Open
|
October 29, 2020
Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors
Changxia Shao, Gerald Li, Lingkang Huang, et al.
Molecular Diagnosis & Therapy
|
September 20, 2022
Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate
Ji Min Kim, Binnari Kim, Eunji Kim, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 13, 2020
Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer
Estrid Høgdall, Claus Høgdall, Thao Vo, et al.
Journal of Hepatology
|
December 15, 2010
Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma
Chun-Fang Xu, Brian H Reck, Vicki L Goodman, et al.
Breast Cancer Research : BCR
|
March 12, 2025
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study
Rebecca Dent, Javier Cortés, Yeon Hee Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Razvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, et al.
NPJ Breast Cancer
|
October 2, 2025
Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy
Javier Cortes, Oleg Lipatov, Seock-Ah Im, et al.
Journal for Immunotherapy of Cancer
|
February 26, 2022
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
Robert I Haddad, Tanguy Y Seiwert, Laura Q M Chow, et al.
The Journal of Pathology. Clinical Research
|
April 17, 2024
Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119
Javier Cortes, Eric P Winer, Oleg Lipatov, et al.
Page
of 3